{"name":"Anesiva, Inc.","slug":"anesiva-inc","ticker":"","exchange":"","domain":"","description":"Anesiva, Inc. is a biopharmaceutical company focused on developing innovative treatments for pain management and other neurological conditions. The company has a pipeline of six drug candidates, with a focus on advancing CGT003 (E2F Duplex Decoy) and NF-kappaB Decoy through clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CGT003 (E2F Duplex Decoy)","genericName":"CGT003 (E2F Duplex Decoy)","slug":"cgt003-e2f-duplex-decoy","indication":"Solid tumors (specific indication under investigation in phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"CGT003 (E2F Duplex Decoy)","genericName":"CGT003 (E2F Duplex Decoy)","slug":"cgt003-e2f-duplex-decoy","phase":"phase_3","mechanism":"CGT003 is a decoy oligonucleotide that binds and sequesters E2F transcription factors, blocking their ability to drive cell proliferation and survival.","indications":["Solid tumors (specific indication under investigation in phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQVHNLT0hnZGR4S19zcTFaS0l4TVNtS1pwSUxEWWJ6bDZuWEJQQzZVcUtsVmxsdE8tdWRjbklSUHRlR1ZQdFJwbU5pUzhEeV9faWdFTVJhekJWSTBDdFd2NTk1TzhYbW54dG11WTBfbEFiZlNMSU93R21wNzRsdnZwQmR3dlJoUndOY3llLXR6SmFfMW9xSU1HdlhYbzVPTTNiTlhXOE9uTDI3c21zV2ZTUmJvSnN3WUVYdzN4YXRzN3M0QThR?oc=5","date":"2025-05-19","type":"pipeline","source":"BioSpace","summary":"Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors - BioSpace","headline":"Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQNkV3OE9IQ29iYjNmYU16ZlJCaXZjZGZSN0ZsSWxFck5BMGZKU3p6Ym8tdEItYU9uR3RfZ2diRTE5S3JsVC02X1RnVXJXUDVBd3ROTl9FNzcxNHJsSGxGbVViM2t2TGx4bkc2Wk5fN05tLWF1TmhfdFFHSTRzTVRBQXV6Yzd3SlAtMVk2QVZpaW9uNk0?oc=5","date":"2024-07-27","type":"pipeline","source":"Legacy","summary":"John P \"Jay\" McLaughlin - Legacy","headline":"John P \"Jay\" McLaughlin","sentiment":"neutral"},{"date":"2009-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2009-12-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2009-12-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2009-12-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2009-11-16","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2009-11-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2009-11-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2009-10-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2009-10-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}